Verona Pharma, Ltd.: Series A $11.5M

Posted in I - Series A, Q - 4Q11, R - INTERNATIONAL, X - Asthma, X - Inflammation, X - Respiratory, X - Rhinitis

Verona Pharma (United Kingdom) a clinical-stage biotechnology company focused on chronic respiratory diseases and inflammation for asthma, COPD, cough, and rhinitis, closed a $11.5M Series A financing. Participants include Henderson Global Investors.

Feb

2010

Altair Therapeutics, Inc.: Series B $17M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Asthma, X - Respiratory, X - Rhinitis, XX - CA

Altair Therapeutics (San Diego, CA) a clinical-stage biopharmaceutical company focused on antisense therapeutics for asthma and rhinitis, closed a $17M Series B financing. Participants include Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners and Forward Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Oxagen, Ltd.: Series C $25.9M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Asthma, X - Inflammation, X - Respiratory, X - Rhinitis

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

to top of page...